子宫动脉灌注新辅助化疗在Ⅱ期子宫颈癌临床治疗中的应用

目的探讨针对Ⅱ期子宫颈癌患者采用子宫动脉灌注新辅助化疗的临床应用效果。方法选取本院2010年7月至2012年7月收治的63例Ⅱ期子宫颈癌患者作为研究组，所有患者均在手术与放疗前给予子宫动脉灌注新辅助化疗，同期选择仅行常规手术的50例患者作为对照组，观察两组患者的预后效果，并综合比较研究组中Ⅱa期与Ⅱb期病例的治疗效果。结果研究组患者治疗后总有效率为68．3％，对照组总有效率为48．0％，组间比较具有统计学意义（P〈0．05），但研究组中Ⅱa期与Ⅱb期病例的治疗结果比较无统计学意义（P〉0．05）。两组患者的深部间质浸润率比较存在统计学意义（P〈0．05），但Ⅱa期与Ⅱb期患者的预后影响因素比较无统计学意义（P〉0．05）。化疗后毒副反应较为轻微，未对持续治疗产生影响。结论针对Ⅱ期子宫颈癌患者采用子宫动脉灌注新辅助化疗能够提高临床治疗效果，保证手术实施的可行性，提高肿瘤组织清除率。

Clinical experience of the treatment of stage II cervical cancer with neoadjuvant intra-uterine arterial infusion chemotherapy

Objective To discuss the clinical efficacy of neoadjuvant intra-uterine arterial infusion chem- otherapy for the treatment of stage Ⅱ cervical cancer. Methods Sixty-three cases of stage Ⅱ cervical cancer treated in our hospital from July 2010 to July 2012 were selected as experimental group. All pa- tients were given neoadjuvant intra-uterine arterial chemotherapy before surgery and radiotherapy. At the same period, fifty cases treated with routine surgery as control group. Their prognosis was observed and the therapeutic effects on patients with stage Ⅱa and Ⅱb cervical cancer were compared. Results After
treatment, the total efficiency was 68.3% in experimental group, and the total efficiency was 48.0% in control group. Comparison with efficiency and deep stromal invasion between two groups has statistically significant （P 〈 0.05）. But, comparison of the treatment outcomes between stages Ⅱa and Ⅱb and com- parison of prognostic factors between Ⅱa and Ⅱb did not show statistical significance （P 〉 0.05 ）. Adverse reactions were relatively mild after chemotherapy and did not affect the continuous treatment. Conclusions To adopt neoadjuvant intra-uterine arterial chemotherapy for stage Ⅱ cervical cancer can improve the clinical efficacy, ensure the feasibility of surgery, and improve tumor clearance rate.